Use of sphingolipids for reducing high plasma cholesterol...

Details Use of sphingolipids for reducing high plasma cholesterol... Use of sphingolipids for reducing high plasma cholesterol...

2011-06-28

2011-06-28

Weddington, Kevin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S114000

Reexamination Certificate

active

07968529

ABSTRACT:
The present invention is in the field of cholesterol and triglyceride-lowering methods and compositions. In particular, the present invention relates to the use of sphingolipids, more preferably phytosphingosine, sphingosine, sphinganine, ceramide, cerebroside and/or sphingomyelin for lowering the cholesterol and triglyceride levels in a subject and to the use of sphingolipids as a plasma and/or serum cholesterol and triglyceride lowering agent. The invention also encompasses methods of treatment of subjects suffering from high plasma cholesterol and triglyceride levels, as well as food items and supplements with increased sphingolipid levels.

REFERENCES:
patent: 5190876 (1993-03-01), Kinkade, Jr. et al.
patent: 5232837 (1993-08-01), Merrill, Jr. et al.
patent: 5374616 (1994-12-01), Spiegel et al.
patent: 5478860 (1995-12-01), Wheeler et al.
patent: 5519007 (1996-05-01), Della Valle et al.
patent: 5830853 (1998-11-01), Baeckstroem et al.
patent: 6562606 (2003-05-01), Elias et al.
patent: 6610835 (2003-08-01), Liotta et al.
patent: 6713057 (2004-03-01), Chatterjee
patent: 2001/0011076 (2001-08-01), Schwartz et al.
patent: 2002/0182250 (2002-12-01), Hori et al.
patent: 2003/0049286 (2003-03-01), Granger et al.
patent: 2003/0109044 (2003-06-01), Logan et al.
patent: 2004/0047851 (2004-03-01), Tabas et al.
patent: 2004/0063667 (2004-04-01), Kishikawa et al.
patent: 2004/0147615 (2004-07-01), Rinehart et al.
patent: 2004/0171557 (2004-09-01), Iian et al.
patent: 2007/0098808 (2007-05-01), Sampalis
patent: 196 02 108 (1997-07-01), None
patent: 0373038 (1990-06-01), None
patent: 0 988 860 (2000-03-01), None
patent: 1 291 340 (2003-03-01), None
patent: 1 452 181 (2004-09-01), None
patent: 2 492 259 (1982-04-01), None
patent: 2 820 037 (2002-08-01), None
patent: 61152632 (1986-07-01), None
patent: 63 044842 (1998-02-01), None
patent: 11 269074 (1999-10-01), None
patent: 2000 350563 (2000-12-01), None
patent: 2001 158735 (2001-06-01), None
patent: 2001 158736 (2001-06-01), None
patent: 2001 213858 (2001-08-01), None
patent: 2002/068998 (2002-03-01), None
patent: 2002 226394 (2002-08-01), None
patent: 2003 137894 (2003-05-01), None
patent: 2001 008 569 (2001-02-01), None
patent: WO 92/03129 (1992-03-01), None
patent: WO 95/32002 (1995-11-01), None
patent: WO 97/11706 (1997-04-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 02/34062 (2002-05-01), None
patent: WO 02/102394 (2002-12-01), None
patent: WO 03/011873 (2003-02-01), None
patent: WO 03/088761 (2003-10-01), None
patent: WO 03/096983 (2003-11-01), None
patent: WO 2004/016257 (2004-02-01), None
patent: WO 2004/064819 (2004-08-01), None
patent: WO 2004/064820 (2004-08-01), None
patent: WO 2004/064823 (2004-08-01), None
patent: WO 2004/096140 (2004-11-01), None
Eckhardt et al., “Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers”, Gastroenterology, vol. 122, No. 4, pp. 948-956 (Apr. 2002), enclosed abstract.
Jiang, Xian-Cheng et al.: “Plasma sphingomyelin level as a risk factor for coronary artery disease” Arteriosclerosis Thrombosis and Vascular Biology, vol. 20, No. 12, Dec. 2000, pp. 2614-2618.
Leventhal, A. R. et al.: “Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux.” The Journal of Biological Chemistry. Nov. 30, 2001, vol. 276, No. 48, pp. 44976-44983.
Chatterjee, Subroto: “Sphingolipids in atherosclerosis and vascular biology” Arteriosclerosis Thrombosis and Vascular Biology, vol. 18, No. 10, Oct. 1998, pp. 1523-1533.
Auge, Nathalie et al.: “Sphingomyelin metabolites in vascular cell signaling and atherogensis” Progress in Lipid Research, vol. 39, No. 3, May 2000, pp. 207-229.
Beers, M.H. and R. Berkow: “The Merck Manual of Diagnosis and Therapy, seventeenth edition” 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002311213 p. 1655, col. 1, paragraph 4-p. 1656, col. 1, paragraph 3.
Beers, M.H. and R. Berkow: “The Merck Manual of Diagnosis and Therapy, seventeenth edition” 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002341450 p. 1062; tables 148-4.
Bibel, D. J. et al.: “Antimicrobial Activity of Sphingosines” Journal of Investigative Dermatology, vol. 98, No. 3, 1992, pp. 269-273.
Bischoff, A. et al.: “Sphingosine-1-Phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro” British Journal of Pharmacology, Basingstoke, Hants, GB, vol. 130, No. 8, Aug. 2000, pp. 1871-1877.
Chong, P.H. et al.: “Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.” Pharmacotherapy, vol. 17(6), pp. 1157-1177; 1997.
Chung, N. et al.: “Phytosphingosine as a specific inhibitor of growth and nutrient import inSaccharomyces cerevisiae.” The Journal of Biological Chemistry. United States Sep. 21, 2001, vol. 276, No. 38, pp. 35614-35621.
Davaille et al. 2000. J. Biol. Chem., vol. 275, No. 44, pp. 34628-34633.
Fantini, J. et al.: “Synthetic Soluble Analogs of Galactosylceramide (GalCer) Bind to the V3 Domain of HIV-1 gp120 and Inhibit HIV-1-induced Fusion and Entry” Journal of Biological Chemistry, vol. 272, No. 11, 1997, pp. 7245-7252.
Howell et al. 2002. Current Organic Chemistry, vol. 6, No. 4, 2002, pp. 365-391.
Jung et al. 1996. Journal of Natural Products, vol. 59, No. 3, pp. 319-322.
Kim, et al. 2000. Phytotherapy Res., 14(6), 448-451.
Mei Jie et al.: “C2—CEramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-I1 adipocytes.” Diabetes, vol. 51(3), pp. 631-637; 2002.
Merrill Jr., A. H. et al.: “Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases” Journal of Nutrition 1995 United States, vol. 125, No. 6 Suppl., 1995, pp. 1677S-1682S.
Ortenberg et al: Farmakologiya i Toksikologiya (Moscow), vol. 47, No. 4, 1984, pp. 102-105.
Rueda, R. et al.: “Addition of gangliosides to an adapted milk formula modifies levels of fecalEscherichia coliin preterm newborn infants” J. Pediatr., vol. 133, 1998, pp. 90-94.
Schmelz, E. M. et al.: “Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in cf1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis” Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 56, No. 21, Nov. 1, 1996, pp. 4936-4941.
Sosnowski et al. 1997. Journal of Urology, vol. 158, No. 1, pp. 269-274.
Sprong, R.C. et al.: “Bovine milk fat components inhibit food-borne pathogens.” International Dairy Journal, vol. 12, pp. 209-215, 2002.
Thurman et al. 1994. Transplant Int.: Off. J. Eur. Soc. For Organ Transplantation. 1994, vol. 7 suppl 1, 1994, pp. s167-s170.
Turinsky J et al: “Effect of sphingoid bases on basal and insulin-induced glucose uptake by skeletal muscle”, Journal of Cell Biology, vol. 115, No. 3 Part 2, 1991, p. 222A; & abstracts of papers presented at the thirty-first annual meeting of the american society for cell bi.
Van Veldhoven Paul P et al: “Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)?” ; Cellular Signaling, vol. 12, No. 7, Jul. 2000, pp. 475-479, p. 477, col. 2, lines 13-29.
Vesper, H. et al.: “Sphingolipids in Food and the Emerging Importance of Sphingolipids to Nutrition” Journal of Nutrition, vol. 129, 1999, pp. 1239-1250.
Viola, G. et al.: “Absorption and distribution of arachidonate in rats receiving lysophospholipids by oral route” Journal of Lipid Research, Bethesda, MD, US, vol. 34, No. 11, 1993, pp. 1843-1852.
Yamada, T. et al.:

Affiliated with

Also associated with

Rating

Use of sphingolipids for reducing high plasma cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of sphingolipids for reducing high plasma cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of sphingolipids for reducing high plasma cholesterol... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2745663